Evidence map›Paper›PMID 35757411›Full record

ArticleFrontiers in endocrinology2022

Genotype, Mortality, Morbidity, and Outcomes of 3β-Hydroxysteroid Dehydrogenase Deficiency in Algeria.

Asmahane Ladjouze, Malcolm Donaldson, Ingrid Plotton, Nacima Djenane, Kahina Mohammedi, Véronique Tardy-Guidollet, Delphine Mallet, Kamélia Boulesnane, Zair Bouzerar, Yves Morel and 1 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in endocrinology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
2.9field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 34 citations in OpenAlex.

  1. Pooled it
  2. Knockout ofZoological research · 2026
    Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 3 countries.

Asmahane LadjouzeDepartment of Paediatrics, Centre Hospitalo-Universitaire Bab El Oued, Algiers, Algeria.
Malcolm DonaldsonSection of Child Health, School of Medicine, Queen Elizabeth University Hospital, Glasgow, United Kingdom.
Ingrid PlottonMolecular Endocrinology and Rare Diseases, Hospices Civils de Lyon, Lyon University Hospital, Bron-Lyon, France.
Nacima DjenaneDepartment of Pathological Anatomy, Centre Hospitalo-Universitaire Bab El Oued, Algiers, Algeria.
Kahina MohammediDepartment of Paediatrics, Centre Hospitalo-Universitaire Bab El Oued, Algiers, Algeria.
Véronique Tardy-GuidolletMolecular Endocrinology and Rare Diseases, Hospices Civils de Lyon, Lyon University Hospital, Bron-Lyon, France.
Delphine MalletMolecular Endocrinology and Rare Diseases, Hospices Civils de Lyon, Lyon University Hospital, Bron-Lyon, France.
Kamélia BoulesnaneDepartment of Paediatrics, Centre Hospitalo-Universitaire Bab El Oued, Algiers, Algeria.
Zair BouzerarDepartment of Paediatrics, Centre Hospitalo-Universitaire Bab El Oued, Algiers, Algeria.
Yves MorelMolecular Endocrinology and Rare Diseases, Hospices Civils de Lyon, Lyon University Hospital, Bron-Lyon, France.
Florence Roucher-BoulezMolecular Endocrinology and Rare Diseases, Hospices Civils de Lyon, Lyon University Hospital, Bron-Lyon, France.
Centre Hospitalo-Universitaire Bab El Oued · DZHospices Civils de Lyon · FRQueen Elizabeth University Hospital · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: 3β-hydroxysteroid dehydrogenase 2 (3βHSD2) deficiency is a rare form of congenital adrenal hyperplasia (CAH), with fewer than 200 cases reported in the world literature and few data on outcomes. Patients and Methods: We report a mixed longitudinal and cross-sectional study from a single Algerian center between 2007 and 2021. Virilization and under-masculinization were assessed using Prader staging and the external masculinization score (EMS), pubertal development staged according to the system of Tanner. Adrenal steroids were measured using mass spectrophotometry (LC-MS/MS). A genetic analysis of Results: A 3βHSD2 defect was confirmed in 6 males and 8 females from 10 families (8 consanguineous), with p.Pro222Gln mutation in all but two siblings with a novel deletion: c.453_464del or p.(Thr152_Pro155del). Probable 3βHSD2 deficiency was diagnosed retrospectively in a further 6 siblings who died, and in two patients from two other centers. In the genetically confirmed patients, the median (range) age at presentation was 20 (0-390) days, with salt-wasting (n = 14) and genital anomaly (n = 10). The Prader stage for female patients was 2 (1-2) with no posterior fusion of the labia. The EMS for males was 6 (3-9). Median (range) values at diagnosis for 17-hydroxyprogesterone (17-OHP), dehydroepiandrosterone sulfate (DHEA-S), and 17-hydroxypregnenolone (17OHPreg) were elevated: 73.7 (0.37-164.3) nmol/L; 501.2(9.4-5441.3) nmol/L, and 139.7 (10.9-1500) nmol/l (NB >90 nmol/L diagnostic of 3βHSD2 defect). Premature pubarche was observed in four patients (3F:1M). Six patients (5F:1M) entered puberty spontaneously, aged 11 (5-13) years in 5 girls and 11.5 years in one boy. Testicular adrenal rest tumors were found in three boys. Four girls reached menarche at 14.3 (11-14.5) years, with three developing adrenal masses (surgically excised in two) and polycystic ovary syndrome (PCOS), with radiological evidence of ovarian adrenal rest tumor in one. The median IQ was 90 (43-105), >100 in only two patients and <70 in three. Conclusions: The prevalence of 3βHSD2 deficiency in Algeria appears high, with p.Pro222Gln being the most frequent mutation. Mortality is also high, with significant morbidity from adrenal tumors and PCOS in adolescence and an increased risk of learning disability. The finding of adrenal tumors in older patients with 3βHSD2 indicates under-replacement, requiring effective hydrocortisone and fludrocortisone treatment rather than surgical removal.

Indexed as

Adrenal Gland NeoplasmsAdrenal Hyperplasia, CongenitalPolycystic Ovary SyndromeAdolescentAgedAlgeriaChromatography, LiquidCross-Sectional StudiesFemaleGenotypeHumansMaleMorbidityRetrospective StudiesTandem Mass Spectrometry3βHSD23-β hydroxysteroid dehydrogenase deficiencyadrenal rest tumorscongenital adrenal hyperplasiaHSD3B2newborn screeningpolycystic ovary syndrome

Identifiers

PMID35757411
PMCPMC9229600
OpenAlexW4281644649

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.